Amy Valley, vice president for Clinical Strategy and Technology Solutions at Cardinal Health, discusses challenges presented within the oncology community, and how Cardinal Health is addressing these issues.
Cost management utilization tools can overcome access barriers to care within the oncology community that often falls short with the use of prior authorization, said Amy Valley, vice president for Clinical Strategy and Technology Solutions at Cardinal Health.
Transcript
What are you the most excited about or looking forward to this year at the 2023 Community Oncology Alliance Community Oncology Conference?
It's always exciting to reconnect with colleagues. I really enjoy just seeing all the people that I've known over the years in community oncology. I'm really excited this year that we are launching a new tool called Care Exchange, which will help practices have a better understanding of total cost of care, as they're navigating value-based reimbursement programs. So, very excited to be able to share that with the attendees.
You have identified many current challenges with prior authorization in oncology care. Are you hopeful that any of the recent attention from Congress on this issue will make a difference?
I am hopeful. I think the reality though will be that it will take time. I think, ultimately, we would like the prior authorization process to be dramatically changed in order to remove the barriers to getting patients on therapy in a timely fashion. But, I think those changes will be slow.
I think that payers will hang on to that as one of the few utilization management tools that they have that they feel comfortable with and they can operate. And it's hard to drive that change.
From my perspective, we're still avidly investing in tools to help alleviate the burden of prior authorization. And especially if you think about the practices, work, staff challenges that they have right now, that anything you can do to save time and to allow the staff to overcome these administrative burdens is of high value. Because of that, we're very interested in being able to make prior authorizations not so cumbersome for them to manage. Hopefully we save them time. And we can, again get patients on therapy in a more efficient manner.
Stagnation in Reimbursement Keeps Biomedical Innovation From Reaching All Patients, COA Panel Says
September 9th 2025Panelists at the Community Oncology Alliance Payer Exchange Summit discuss the urgent need for innovative reimbursement models in cancer care to match advancements in biomedical technology and drug discovery.
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
CNS Metastases in EGFR-Mutant NSCLC: Emerging Therapeutic Strategies and Ongoing Challenges
September 8th 2025Central nervous system (CNS) metastases in EGFR-mutant non–small cell lung cancer (NSCLC) remain a major challenge, with emerging therapies and evolving trial designs aiming to improve outcomes and address unmet needs.
Read More
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
Stagnation in Reimbursement Keeps Biomedical Innovation From Reaching All Patients, COA Panel Says
September 9th 2025Panelists at the Community Oncology Alliance Payer Exchange Summit discuss the urgent need for innovative reimbursement models in cancer care to match advancements in biomedical technology and drug discovery.
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
CNS Metastases in EGFR-Mutant NSCLC: Emerging Therapeutic Strategies and Ongoing Challenges
September 8th 2025Central nervous system (CNS) metastases in EGFR-mutant non–small cell lung cancer (NSCLC) remain a major challenge, with emerging therapies and evolving trial designs aiming to improve outcomes and address unmet needs.
Read More
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
2 Commerce Drive
Cranbury, NJ 08512